Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1981 1
1986 1
1991 1
1994 1
1995 1
1996 1
1997 2
1998 4
1999 3
2000 2
2001 3
2002 1
2003 11
2004 7
2005 14
2006 12
2007 13
2008 15
2009 25
2010 31
2011 26
2012 21
2013 23
2014 22
2015 17
2016 27
2017 20
2018 19
2019 25
2020 18
2021 15
2022 17
2023 7
2024 8
2025 17
2026 6

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

359 results

Results by year

Filters applied: . Clear all
Page 1
Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial.
Leder BZ, Tsai JN, Uihlein AV, Wallace PM, Lee H, Neer RM, Burnett-Bowie SA. Leder BZ, et al. Lancet. 2015 Sep 19;386(9999):1147-55. doi: 10.1016/S0140-6736(15)61120-5. Epub 2015 Jul 2. Lancet. 2015. PMID: 26144908 Free PMC article. Clinical Trial.
In DATA-Switch, women originally assigned to teriparatide received denosumab (teriparatide to denosumab group), those originally assigned to denosumab received teriparatide (denosumab to teriparatide group), and those originally assigned to both receiv …
In DATA-Switch, women originally assigned to teriparatide received denosumab (teriparatide to denosumab group), those original …
Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial.
Tsai JN, Uihlein AV, Lee H, Kumbhani R, Siwila-Sackman E, McKay EA, Burnett-Bowie SA, Neer RM, Leder BZ. Tsai JN, et al. Lancet. 2013 Jul 6;382(9886):50-6. doi: 10.1016/S0140-6736(13)60856-9. Epub 2013 May 15. Lancet. 2013. PMID: 23683600 Free PMC article. Clinical Trial.
At 12 months, posterior-anterior lumbar spine BMD increased more in the combination group (9.1%, [SD 3.9]) than in the teriparatide (6.2% [4.6], p=0.0139) or denosumab (5.5% [3.3], p=0.0005) groups. Femoral-neck BMD also increased more in the combination group (4.2% [3.0]) …
At 12 months, posterior-anterior lumbar spine BMD increased more in the combination group (9.1%, [SD 3.9]) than in the teriparatide ( …
Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial.
Kendler DL, Marin F, Zerbini CAF, Russo LA, Greenspan SL, Zikan V, Bagur A, Malouf-Sierra J, Lakatos P, Fahrleitner-Pammer A, Lespessailles E, Minisola S, Body JJ, Geusens P, Möricke R, López-Romero P. Kendler DL, et al. Lancet. 2018 Jan 20;391(10117):230-240. doi: 10.1016/S0140-6736(17)32137-2. Epub 2017 Nov 9. Lancet. 2018. PMID: 29129436 Clinical Trial.
Clinical fractures occurred in 30 (4.8%) of 680 patients in the teriparatide group compared with 61 (9.8%) of 680 in the risedronate group (hazard ratio 0.48, 95% CI 0.32-0.74; p=0.0009). Non-vertebral fragility fractures occurred in 25 (4.0%) patients in the teriparati …
Clinical fractures occurred in 30 (4.8%) of 680 patients in the teriparatide group compared with 61 (9.8%) of 680 in the risedronate …
Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial.
Miller PD, Hattersley G, Riis BJ, Williams GC, Lau E, Russo LA, Alexandersen P, Zerbini CA, Hu MY, Harris AG, Fitzpatrick LA, Cosman F, Christiansen C; ACTIVE Study Investigators. Miller PD, et al. JAMA. 2016 Aug 16;316(7):722-33. doi: 10.1001/jama.2016.11136. JAMA. 2016. PMID: 27533157 Clinical Trial.
Hypercalcemia was a prespecified safety end point in abaloparatide-treated vs teriparatide participants. RESULTS: Among 2463 women (mean age, 69 years [range, 49-86]), 1901 completed the study. ...Incidence of hypercalcemia was lower with abaloparatide (3.4%) vs teripar …
Hypercalcemia was a prespecified safety end point in abaloparatide-treated vs teriparatide participants. RESULTS: Among 2463 women (m …
Romosozumab in postmenopausal women with low bone mineral density.
McClung MR, Grauer A, Boonen S, Bolognese MA, Brown JP, Diez-Perez A, Langdahl BL, Reginster JY, Zanchetta JR, Wasserman SM, Katz L, Maddox J, Yang YC, Libanati C, Bone HG. McClung MR, et al. N Engl J Med. 2014 Jan 30;370(5):412-20. doi: 10.1056/NEJMoa1305224. Epub 2014 Jan 1. N Engl J Med. 2014. PMID: 24382002 Free article. Clinical Trial.
Participants were randomly assigned to receive subcutaneous romosozumab monthly (at a dose of 70 mg, 140 mg, or 210 mg) or every 3 months (140 mg or 210 mg), subcutaneous placebo, or an open-label active comparator--oral alendronate (70 mg weekly) or subcutaneous teriparatide …
Participants were randomly assigned to receive subcutaneous romosozumab monthly (at a dose of 70 mg, 140 mg, or 210 mg) or every 3 months (1 …
Teriparatide Promotes Bone Healing in Medication-Related Osteonecrosis of the Jaw: A Placebo-Controlled, Randomized Trial.
Sim IW, Borromeo GL, Tsao C, Hardiman R, Hofman MS, Papatziamos Hjelle C, Siddique M, Cook GJR, Seymour JF, Ebeling PR. Sim IW, et al. J Clin Oncol. 2020 Sep 10;38(26):2971-2980. doi: 10.1200/JCO.19.02192. Epub 2020 Jul 2. J Clin Oncol. 2020. PMID: 32614699 Clinical Trial.
Teriparatide was also associated with reduced bony defects at week 52 (OR, 8.1; P = .017). The incidence of adverse events was balanced between groups, including nausea, anorexia, and musculoskeletal pain, most of mild severity. CONCLUSION: Teriparatide improves the …
Teriparatide was also associated with reduced bony defects at week 52 (OR, 8.1; P = .017). The incidence of adverse events was balanc …
Randomized controlled trial of daily teriparatide, weekly high-dose teriparatide, or bisphosphonate in patients with postmenopausal osteoporosis: The TERABIT study.
Chiba K, Okazaki N, Kurogi A, Watanabe T, Mori A, Suzuki N, Adachi K, Era M, Yokota K, Inoue T, Yabe Y, Furukawa K, Kondo C, Tsuda K, Ota S, Isobe Y, Miyazaki S, Morimoto S, Sato S, Nakashima S, Tashiro S, Yonekura A, Tomita M, Osaki M. Chiba K, et al. Bone. 2022 Jul;160:116416. doi: 10.1016/j.bone.2022.116416. Epub 2022 Apr 6. Bone. 2022. PMID: 35398293 Free article. Clinical Trial.
PURPOSE: The effects of daily teriparatide (20 mug) (D-PTH), weekly high-dose teriparatide (56.5 mug) (W-PTH), or bisphosphonates (BPs) on areal bone mineral density (aBMD), bone turnover markers (BTMs), volumetric BMD (vBMD), microarchitecture, and estimated streng …
PURPOSE: The effects of daily teriparatide (20 mug) (D-PTH), weekly high-dose teriparatide (56.5 mug) (W-PTH), or bisphosphona …
A randomized controlled trial of teriparatide for accelerating bone union and improving clinical outcomes in patients with pertrochanteric fracture fixation.
Tanavalee C, Ngarmukos S, Amarase C, Tantavisut S, Jaruthien N, Tanavalee A. Tanavalee C, et al. Sci Rep. 2025 Jun 3;15(1):19465. doi: 10.1038/s41598-025-03720-2. Sci Rep. 2025. PMID: 40461584 Free PMC article. Clinical Trial.
In conclusion, a 12-week teriparatide administration following intertrochanteric fracture fixation significantly shortened the fracture healing time. Although there were no differences in improved clinical outcomes, the teriparatide group had less decline in BMD at …
In conclusion, a 12-week teriparatide administration following intertrochanteric fracture fixation significantly shortened the fractu …
Probability of achieving bone mineral density treatment targets with abaloparatide and teriparatide.
Cosman F, Mitlak BH, Wang Y, Pearman L, Moreira CA, Lewiecki EM, Cummings SR. Cosman F, et al. J Bone Miner Res. 2025 Jun 3;40(6):773-778. doi: 10.1093/jbmr/zjaf053. J Bone Miner Res. 2025. PMID: 40214193 Free PMC article. Clinical Trial.
Over 18 mo of treatment, more than 50% of women were likely to achieve TH T-scores >-2.5, with baseline TH T-scores as low as -2.7 for both abaloparatide and teriparatide. More than 50% of women were predicted to achieve an LS T-score >-2.5 with a baseline LS T-score …
Over 18 mo of treatment, more than 50% of women were likely to achieve TH T-scores >-2.5, with baseline TH T-scores as low as -2.7 for bo …
359 results